Dr. Garassino Discusses Promising Findings With Osimertinib for Patients With NSCLC and Brain Mets

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non—small cell lung cancer (NSCLC) who also harbor brain metastases.

Related Content:

ASCO Annual MeetingConferenceLung Cancer
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
Defining Resectability in Stage III NSCLC: Addressing Key Controversies
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC